{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.00"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day -3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.00"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day -2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.00"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day -1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.20","value":"0.04"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.20","value":"0.04"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.27","value":"0.08"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.39","value":"0.08"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.43","value":"0.12"},{"groupId":"OG001","spread":"0.20","value":"0.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.43","value":"0.12"},{"groupId":"OG001","spread":"0.28","value":"0.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.46","value":"0.15"},{"groupId":"OG001","spread":"0.28","value":"0.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.27","value":"0.08"},{"groupId":"OG001","spread":"0.28","value":"0.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.27","value":"0.08"},{"groupId":"OG001","spread":"0.20","value":"0.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.37","value":"0.15"},{"groupId":"OG001","spread":"0.28","value":"0.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.33","value":"0.12"},{"groupId":"OG001","spread":"0.28","value":"0.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.37","value":"0.15"},{"groupId":"OG001","spread":"0.20","value":"0.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.37","value":"0.16"},{"groupId":"OG001","spread":"0.28","value":"0.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Day 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.20","value":"0.04"},{"groupId":"OG001","spread":"0.29","value":"0.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Day 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.28","value":"0.08"},{"groupId":"OG001","spread":"0.29","value":"0.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Day 14"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"Grade 0 hemorrhoids is defined as no hemorrhoids. Grade 1 hemorrhoids is defined as asymptomatic; clinical or diagnostic observations only; intervention not indicated. Grade 2 hemorrhoids is defined as symptomatic; banding or medical intervention indicated. Grade 3 hemorrhoids is defined as severe symptoms; invasive intervention indicated. There is no grade 4 or 5 hemorrhoids defined in the CTCAE v5.0.","dispersionType":"Standard Deviation","groups":[{"description":"Patients will receive six doses of Uproleselan intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.","id":"OG000","title":"Uproleselan + Standard of Care Melphalan"},{"description":"Patients will receive six doses of placebo intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.","id":"OG001","title":"Placebo + Standard of Care Melphalan"}],"paramType":"MEAN","populationDescription":"The number of participants analyzed at each time point may differ from the overall number of participants analyzed because the data was not collected. One patient in the placebo + standard of care melphalan arm was not evaluable for the outcome measure.","reportingStatus":"POSTED","timeFrame":"From day -3 to date of discharge or day 14 (whichever is sooner) (up to be 18 days)","title":"Change in Hemorrhoids as Assessed Per CTCAE v5.0","type":"SECONDARY","unitOfMeasure":"CTCAE grade"}